Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic ...
1 day ago · Sage Therapeutics has officially rejected Biogen’s unsolicited takeover bid and will instead undergo a strategic review that could ultimately end up in a transaction of some kind. Sage’s board unanimously rejected the bid, arguing that the proposed $469 million significantly undervalued the company and is not in the best interest of ...
Sage rejects Biogen's $469 million takeover offer, says offer ...
1 day ago · Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. Shares of Sage were up 5.3% at $7.48 in early trading.
Sage rejects Biogen takeover and launches review
15 hours ago · Biogen – which has a longstanding alliance in place with Sage and co-markets Zurzuvae – offered to buy the approximately 90% of shares in Sage that it doesn't already own for $7.22 apiece ...
Sage rebuffs Biogen bid to take it over | BioPharma Dive
2 days ago · Dive Brief: Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a takeover, unanimously rejecting a $469 million offer from Biogen it said “significantly undervalues” the company. Earlier this month, Biogen proposed to buy Sage for $7.22 per share, which represented about a 30% premium to Sage’s share price at the time.
Sage rejects Biogen’s $469m takeover bid - Pharmaceutical …
15 hours ago · Sage’s board has stated it will consider “strategic alternatives” to maximise shareholder value. Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that …
Sage seeks injunction after Biogen's unsolicited buyout offer
Jan 21, 2025 · Biogen’s offer, at about $469 million, effectively assigns Sage a negative value because the Massachusetts biotech had about $569 million in cash and equivalents at the end of September.
Sage Therapeutics rejects Biogen’s buyout offer, explores …
1 day ago · Sage rejects Biogen’s buyout offer, but says it's open to deals. expand. Barry Greene is the CEO of Sage Therapeutics. Courtesy photo. By Hannah Green – Reporter, Boston Business Journal.
Sage Rejects Biogen Bid, Launches Review of Alternatives
1 day ago · Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...
Sage Therapeutics Announces Discontinuation of the …
Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their shared vision to help women suffering from PPD.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
1 day ago · Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage ...
- Some results have been removed